177 431

Cited 0 times in

Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection

 Jung Ar Shin  ;  Yoon Soo Chang  ;  Hyung Jung Kim  ;  Se Kyu Kim  ;  Joon Chang  ;  Chul Min Ahn  ;  Min Kwang Byun 
 YONSEI MEDICAL JOURNAL, Vol.53(5) : 974-984, 2012 
Journal Title
Issue Date
Acinetobacter Infections/drug therapy* ; Acinetobacter baumannii/drug effects ; Acinetobacter baumannii/pathogenicity* ; Aged ; Anti-Bacterial Agents/therapeutic use* ; Drug Resistance, Multiple, Bacterial ; Female ; Humans ; Male ; Middle Aged ; Minocycline/analogs & derivatives* ; Minocycline/therapeutic use ; Retrospective Studies ; Treatment Outcome
Acinetobacter baumannii ; bacteremia ; multidrug resistance ; tigecycline ; ventilator-associated pneumonia
PURPOSE: Acinetobacter baumannii (A. baumannii) has emerged as a major cause of nosocomial pneumonia and sepsis in seriously ill patients. Multidrug-resistant A. baumannii (MDRAB) is increasing in frequency, and the management of it's infections is consequently difficult. Therefore, tigecycline is considered to be the drug of choice for MDRAB treatment. The aim of our study was to evaluate the microbiological eradication and clinical effectiveness of tigecycline against MDRAB in seriously ill patients, including patients with ventilator-associated pneumonia (VAP). MATERIALS AND METHODS: We conducted a retrospective study including patients with A. baumannii infections who were treated with tigecycline between April 1, 2009 and March 31, 2010. We treated 27 patients with tigecycline for MDRAB infections. RESULTS: The mean age of patients was 66.2 years, and 20 (74.1%) patients were male. The median length of stay at hospital was 74.6 days. MDRAB was eradicated from the site of infection in 23 cases (85.2%), however, only 17 cases (63.0%) showed positive clinical responses. Overall, an in-hospital mortality rate of 51.9% was observed, and 4 cases of death were attributable to sepsis. The combination therapy showed better clinical and microbial success rates than the monotherapy without significant difference. CONCLUSION: We observed the relatively low clinical success rate although the microbial eradication rate was high, probably due to superinfections in VAP and bacteremia. We suggest that clinicians should limit tigecycline monotherapy for MDRAB infection in critically ill patients, until large controlled clinical trials should be conducted.
Files in This Item:
T201202536.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Se Kyu(김세규)
Kim, Hyung Jung(김형중) ORCID logo https://orcid.org/0000-0003-2498-0683
Byun, Min Kwang(변민광) ORCID logo https://orcid.org/0000-0003-1525-1745
Shin, Jung Ar(신정아)
Ahn, Chul Min(안철민)
Chang, Yoon Soo(장윤수) ORCID logo https://orcid.org/0000-0003-3340-4223
Chang, Joon(장준) ORCID logo https://orcid.org/0000-0003-4542-6841
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.